FDA
-
-
-
-
-
-
-
Auris Medical (EARS) Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
-
-
-
-
-
-
-
Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results
-
-
-
-
-
-
-
Auris Medical Holding (EARS) Announces Publication of AM-111 Phase 3 Results in Otology & Neurotology
-
-
-
-
-
-
-
Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
-
-
-
-
-
-
-
Auris Medical Provides Update on AM-111 Development Program
-
-
-
-
-
-
-
Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study
-
-
-
-
-
-
-
Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo
322,902 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

